Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 486 participants.
Also called NCT06447701
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 486 participants
- Sponsor
- Registry
-
NCT06447701
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06447701. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-30 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
- Acronym
- IRIS-sICAS
- Condition
- Brain Diseases
- Condition
- Ischemic Stroke
- Condition
- Ischemia
- Condition
- Stroke
- Condition
- Cerebral Infarction
- Condition
- Atherosclerosis of Artery
- Condition
- Atheroscleroses, Intracranial
- Intervention (Drug)
- Tocilizumab
- Intervention (Drug)
- NaCl 0.9% 100ml
- Lead sponsor
- Zhujiang Hospital
- Collaborator
- Shenzhen Second People's Hospital
- Collaborator
- Central People's Hospital of Zhanjiang
- Collaborator
- Shantou Central Hospital
- Collaborator
- Eighth Affiliated Hospital, Sun Yat-sen University
- Collaborator
- Guangzhou First People's Hospital
- Collaborator
- Peking University Shenzhen Hospital
- Collaborator
- Guangdong Provincial People's Hospital
Record details
- Record id
cardio:ct-nct06447701- Content hash
acb801452a9866f666e24c9a90ba1caeaeab15e99925d55e1d6c63297c19fe7e